Panulisib, also known as AK151761, is a potent and selective imidazoquinoline based PI3K inhibitor with potential anticancer activity.
For research use only. We do not sell to patients.
Chemical Information
Name | Panulisib |
Iupac Chemical Name | (E)-N-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-ylidene)cyanamide |
Synonyms | AK151761 ; AK 151761 |
Molecular Formula | C27H20F3N9 |
Molecular Weight | 527.50321 |
Smile | NC1=C(C=C(C=N1)C1=CC=2C3=C(C=NC2C=C1)N(/C(/N3C=3C=NC(=CC3)C(C)(C)C#N)=N\C#N)C)C(F)(F)F |
InChiKey | VJLRLTSXTLICIR-AUGOTPMTSA-N |
InChi | InChI=1S/C27H20F3N9/c1-26(2,13-31)22-7-5-17(11-35-22)39-23-18-8-15(16-9-19(27(28,29)30)24(33)36-10-16)4-6-20(18)34-12-21(23)38(3)25(39)37-14-32/h4-12H,1-3H3,(H2,33,36)/b37-25+ |
CAS Number | 1356033-60-7 |
Related CAS | |
Ordering Information
Packaging | Price | Availability | Purity | Shipping Time |
Bulk | | Enquiry | Enquiry | Enquiry |
Formulation | Solid powder |
Purity | 98% by HPLC |
Storage | -20 ºC for 3 years |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature |
HS Code | |
Targets | |
Mechanism | |
Cell study | |
Animal study | |
Clinical study | |